Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials
Identifieur interne : 001813 ( Main/Exploration ); précédent : 001812; suivant : 001814Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials
Auteurs : Cristina Sampaio [Portugal] ; Juliana Bronzova [Pays-Bas] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Serge V. Van De Witte [Pays-Bas] ; And Ad Theeuwes [Pays-Bas]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-07.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
This report presents the results of 2 randomized trials—Rembrandt and Vermeer—on the efficacy and safety of pardoprunox in patients with early Parkinson's disease. Patients with Parkinson's disease with a Unified Parkinson's Disease Rating Scale–Motor score ≥ 10 and modified Hoehn and Yahr stage ≤ 3 were randomized to pardoprunox (fixed doses of 6 mg/day [n = 115] or 12 mg/day [n = 118] or a flexible‐dose range of 12–42 mg/day [n = 116]) or placebo (n = 119) in Rembrandt and pardoprunox 12–42 mg/day (n = 108), pramipexole 1.5–4.5 mg/day (n = 116), or placebo (n = 110) in Vermeer. Pardoprunox showed a significant benefit over placebo in the primary efficacy variable, least‐square mean change from baseline in Unified Parkinson's Disease Rating Scale–Motor score: Rembrandt—fixed doses of 6 and 12 mg/day, −6.0 and −4.7 points, respectively; flexible‐dose 12–42 mg/day, −5.5 points; placebo, −2.9 points; Vermeer—flexible‐dose 12–42 mg/day, −4.9 points; placebo, −2.5 points; pramipexole, −5.7 points. No minimum effective dose was established. Secondary efficacy parameters supported the results of the primary efficacy variable. Pardoprunox tolerability was dose related: flexible‐dose 12–42 mg/day showed the highest dropout rate due to treatment‐emergent adverse events (Rembrandt, 56.0%; Vermeer, 46.3%) and overall incidence of treatment‐emergent adverse events (Rembrandt, 97.4%; Vermeer, 92.6%), primarily due to nausea, somnolence, and dizziness. Because pardoprunox showed similar efficacy across all dose groups, these observations suggest that the 12–42 mg/day dose range was higher than therapeutically required. Furthermore, the early onset of treatment‐emergent adverse events and dropouts observed for pardoprunox suggest that titration was too rapid. Pardoprunox significantly improved motor symptoms in patients with early Parkinson's disease, but further investigation into the dose and titration schedule is required to improve tolerability. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23590
Affiliations:
- Canada, France, Pays-Bas, Portugal, États-Unis
- Floride, Midi-Pyrénées, Occitanie (région administrative), Ontario
- Tampa, Toronto, Toulouse
- Université de Floride du Sud, Université de Toronto
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001581
- to stream Istex, to step Curation: 001581
- to stream Istex, to step Checkpoint: 000398
- to stream Main, to step Merge: 001891
- to stream PascalFrancis, to step Corpus: 000296
- to stream PascalFrancis, to step Curation: 000967
- to stream PascalFrancis, to step Checkpoint: 000242
- to stream Main, to step Merge: 001A17
- to stream Main, to step Curation: 001813
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials</title>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</author>
<author><name sortKey="Bronzova, Juliana" sort="Bronzova, Juliana" uniqKey="Bronzova J" first="Juliana" last="Bronzova">Juliana Bronzova</name>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</author>
<author><name sortKey="Van De Witte, Serge V" sort="Van De Witte, Serge V" uniqKey="Van De Witte S" first="Serge V." last="Van De Witte">Serge V. Van De Witte</name>
</author>
<author><name sortKey="Theeuwes, And Ad" sort="Theeuwes, And Ad" uniqKey="Theeuwes A" first="And Ad" last="Theeuwes">And Ad Theeuwes</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:5F1B5BA930CAA821B9BFB5C07BFE579A366E4094</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23590</idno>
<idno type="url">https://api-v5.istex.fr/document/5F1B5BA930CAA821B9BFB5C07BFE579A366E4094/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001581</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001581</idno>
<idno type="wicri:Area/Istex/Curation">001581</idno>
<idno type="wicri:Area/Istex/Checkpoint">000398</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000398</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Sampaio C:pardoprunox:in:early</idno>
<idno type="wicri:Area/Main/Merge">001891</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:11-0353386</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000296</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000967</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000242</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000242</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Sampaio C:pardoprunox:in:early</idno>
<idno type="wicri:Area/Main/Merge">001A17</idno>
<idno type="wicri:Area/Main/Curation">001813</idno>
<idno type="wicri:Area/Main/Exploration">001813</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials</title>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Laboratório de Farmacologia Clinica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Edifício do Hospital de Santa Maria, Lisboa</wicri:regionArea>
<wicri:noRegion>Lisboa</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Laboratório de Farmacologia Clinica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Edifício do Hospital de Santa Maria, Piso 3, Elevador 11, 1600 Lisboa</wicri:regionArea>
<wicri:noRegion>1600 Lisboa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bronzova, Juliana" sort="Bronzova, Juliana" uniqKey="Bronzova J" first="Juliana" last="Bronzova">Juliana Bronzova</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Solvay Pharmaceuticals B.V., (Solvay is now Abbott), Weesp</wicri:regionArea>
<wicri:noRegion>Weesp</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Hospital, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Clinical Pharmacology, Faculty of Medicine, University Hospital of Toulouse, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van De Witte, Serge V" sort="Van De Witte, Serge V" uniqKey="Van De Witte S" first="Serge V." last="Van De Witte">Serge V. Van De Witte</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Solvay Pharmaceuticals B.V., (Solvay is now Abbott), Weesp</wicri:regionArea>
<wicri:noRegion>Weesp</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Theeuwes, And Ad" sort="Theeuwes, And Ad" uniqKey="Theeuwes A" first="And Ad" last="Theeuwes">And Ad Theeuwes</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Solvay Pharmaceuticals B.V., (Solvay is now Abbott), Weesp</wicri:regionArea>
<wicri:noRegion>Weesp</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-07">2011-07</date>
<biblScope unit="volume">26</biblScope>
<biblScope unit="issue">8</biblScope>
<biblScope unit="page" from="1464">1464</biblScope>
<biblScope unit="page" to="1476">1476</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">5F1B5BA930CAA821B9BFB5C07BFE579A366E4094</idno>
<idno type="DOI">10.1002/mds.23590</idno>
<idno type="ArticleID">MDS23590</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine agonist</term>
<term>Nervous system diseases</term>
<term>Pardoprunox</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Partial agonist</term>
<term>pardoprunox (SLV308)</term>
<term>partial dopamine agonist</term>
<term>randomized controlled trial</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Agoniste partiel</term>
<term>Maladie de Parkinson</term>
<term>Pardoprunox</term>
<term>Pathologie du système nerveux</term>
<term>Stimulant dopaminergique</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This report presents the results of 2 randomized trials—Rembrandt and Vermeer—on the efficacy and safety of pardoprunox in patients with early Parkinson's disease. Patients with Parkinson's disease with a Unified Parkinson's Disease Rating Scale–Motor score ≥ 10 and modified Hoehn and Yahr stage ≤ 3 were randomized to pardoprunox (fixed doses of 6 mg/day [n = 115] or 12 mg/day [n = 118] or a flexible‐dose range of 12–42 mg/day [n = 116]) or placebo (n = 119) in Rembrandt and pardoprunox 12–42 mg/day (n = 108), pramipexole 1.5–4.5 mg/day (n = 116), or placebo (n = 110) in Vermeer. Pardoprunox showed a significant benefit over placebo in the primary efficacy variable, least‐square mean change from baseline in Unified Parkinson's Disease Rating Scale–Motor score: Rembrandt—fixed doses of 6 and 12 mg/day, −6.0 and −4.7 points, respectively; flexible‐dose 12–42 mg/day, −5.5 points; placebo, −2.9 points; Vermeer—flexible‐dose 12–42 mg/day, −4.9 points; placebo, −2.5 points; pramipexole, −5.7 points. No minimum effective dose was established. Secondary efficacy parameters supported the results of the primary efficacy variable. Pardoprunox tolerability was dose related: flexible‐dose 12–42 mg/day showed the highest dropout rate due to treatment‐emergent adverse events (Rembrandt, 56.0%; Vermeer, 46.3%) and overall incidence of treatment‐emergent adverse events (Rembrandt, 97.4%; Vermeer, 92.6%), primarily due to nausea, somnolence, and dizziness. Because pardoprunox showed similar efficacy across all dose groups, these observations suggest that the 12–42 mg/day dose range was higher than therapeutically required. Furthermore, the early onset of treatment‐emergent adverse events and dropouts observed for pardoprunox suggest that titration was too rapid. Pardoprunox significantly improved motor symptoms in patients with early Parkinson's disease, but further investigation into the dose and titration schedule is required to improve tolerability. © 2011 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>France</li>
<li>Pays-Bas</li>
<li>Portugal</li>
<li>États-Unis</li>
</country>
<region><li>Floride</li>
<li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
<li>Ontario</li>
</region>
<settlement><li>Tampa</li>
<li>Toronto</li>
<li>Toulouse</li>
</settlement>
<orgName><li>Université de Floride du Sud</li>
<li>Université de Toronto</li>
</orgName>
</list>
<tree><country name="Portugal"><noRegion><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</noRegion>
<name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</country>
<country name="Pays-Bas"><noRegion><name sortKey="Bronzova, Juliana" sort="Bronzova, Juliana" uniqKey="Bronzova J" first="Juliana" last="Bronzova">Juliana Bronzova</name>
</noRegion>
<name sortKey="Theeuwes, And Ad" sort="Theeuwes, And Ad" uniqKey="Theeuwes A" first="And Ad" last="Theeuwes">And Ad Theeuwes</name>
<name sortKey="Van De Witte, Serge V" sort="Van De Witte, Serge V" uniqKey="Van De Witte S" first="Serge V." last="Van De Witte">Serge V. Van De Witte</name>
</country>
<country name="États-Unis"><region name="Floride"><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</region>
</country>
<country name="Canada"><region name="Ontario"><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</region>
</country>
<country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001813 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001813 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:5F1B5BA930CAA821B9BFB5C07BFE579A366E4094 |texte= Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |